GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

NCT05356104 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether a GLP-1 analogue can slow the progression of small vessel disease in the brain among adults with cerebral small vessel disease.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 110 people Planned (estimated).

Who can join Ages 55–80 · all sexes

Timeline Started 2022-05 · est. completion 2026-12

Where 1 site · Hong Kong

What this study is testing ClinicalTrials.gov NCT05356104 ↗

Description as written by the study sponsor.

Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials. The presence of glucagon-like peptide-1 receptor (GLP-1R) in cerebral microglia may reveal a potential therapeutic target for prevention of cSVD progression and its disabling clinical outcomes. At the cellular and animal experimentation levels, GLP-1R agonist demonstrated reversal of some pathogenic processes in cSVD. However, its application to cSVD patients remains to be elucidated. Investigator aims to investigate the safety and efficacy of GLP-1R agonist in patients with moderate-to-severe cSVD.

Treatments tested

Exenatide extended release also known as Bydureon BCise Drug

2mg once weekly via subcutaneous injection

Main thing measured	Change of Brain Peak Width of Skeletonized Mean Diffusivity
Sponsor	Chinese University of Hong Kong
Conditions studied	Cerebral Small Vessel Disease
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05356104 ↗